Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I open-label dose-escalation study of BI 905677 in advanced solid tumours
jRCT2080224086Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2018
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of BI 905677 in Nonhematologic neoplasms and Non-hematologic malignancy, sponsored by Boehringer Ingelheim. Primary endpoints: Maximum tolerated dose of BI 905677, Safety and tolerability of BI 905677 and 2 more. Started Oct 2018; status: terminated.
02
Drugs
BI 905677
03
Conditions
Nonhematologic neoplasmsNon-hematologic malignancy
Beyond the preview
Go deeper on jRCT2080224086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224086.